It has been demonstrated that polymorphisms of aggregation may determine the variability of clinical features in neurodegenerative diseases; likewise, the diversity of p53 aggregation in tumors may change p53 function through various pathways [28]. Here, TP53 is linked to neurodegenerative disease.